BusinessAsianet Newsable
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside
in5points
Outlook Therapeutics' OTLK stock jumped after FDA approval of its wet AMD drug.
The drug targets wet age-related macular degeneration.
Outlook expects a U.S. launch before year-end and 12 years of market exclusivity.
Analysts see nearly 300% upside potential for the stock.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically